Basel, June 6, 2022 — Novartis today announced Tafinlar ® (dabrafenib) + Mekinist ® (trametinib) significantly improved efficacy in patients ages 1 to 17 years old with BRAF V600 pediatric low-grade ...

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today reported updated safety and efficacy data from the Phase 1/2a clinical trial evaluating plixorafenib (FORE8394; PLX8394), a novel, ...

IMspire150 is a Phase III, multi-center, double-blind, placebo-controlled randomized study in people with previously untreated BRAF V600 mutation-positive metastatic or unresectable locally advanced ...

GSK receives EU marketing authorisation for Mekinist™ (trametinib) for patients with unresectable or metastatic melanoma with a BRAF V600 mutation GlaxoSmithKline plc (LSE/NYSE: GSK) today announced ...

--Roche Group’s Personalized Healthcare Approach Demonstrated Through Vemurafenib and its Investigational Companion Diagnostic, Roche’s cobas 4800 BRAF V600 Mutation Test -- CHICAGO--(BUSINESS WIRE)-- ...

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF ...

The largest known prospective study of patients treated with trametinib plus dabrafenib for unresectable advanced melanoma with BRAF-V600 mutation confirmed the combination’s clinical activity.

Dabrafenib (trade name: Tafinlar) has been approved since 2013 for the treatment of adults with advanced, i.e. metastatic or unresectable, melanoma with a BRAF V600 mutation. Since September 2015, ...

Tafinlar plus Mekinist is now approved by the Food and Drug Administration to treat adults and children over the age of 6 who have BRAF V600-mutant advanced solid cancers. The Food and Drug ...

WATERTOWN, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, ...

--Roche Group’s Personalized Healthcare Approach Demonstrated Through Vemurafenib and its Investigational Companion Diagnostic, Roche’s cobas 4800 BRAF V600 Mutation Test -- CHICAGO--(BUSINESS WIRE)-- ...